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KESAN MITRAGININ TERHADAP PEMBENTUKAN CYCLIC AMP DAN 
EKSPRESI mRNA OPIOID MU-RESEPTOR DARIPADA RAWATAN 
KRONIK MORFIN DALAM SEL NEUROBLASTOMA SK-N-SH 
ABSTRAK 
Mitraginin adalah sebatian indole alkaloid daripada pokok Mitragyna 
speciosa (M.speciosa) Korth. (Famili). Di Thailand, tumbuhan ini dikenali sebagai 
"Kratom" dan di Malaysia yang dikenali sebagai "Biak-Biak" dan "Ketum". M. 
speciosa telah digunakan sebagai terapi penggantian untuk rawatan kronik opioid 
dalam menguruskan gejala ketagihan di Malaysia dan Thailand. Sehingga kini lebih 
daripada 40 sebatian telah diasingkan dari daun pokok ini. Mitraginin adalah sebatian 
yang paling banyak daripada 25 alkaloid dalam daun M.speciosa (66% daripada asas 
mentah) dan mempunyai kesan terhadap opioid seperti morphine. 
Pengasingan sebatian bioaktif mitraginin dengan menggunakan kaedah 
ekstrak asid-bes dan kaedah turus kromatografi telah dibangunkan. Dalam kajian ini, 
kami menyiasat mekanisme selular rawatan bersama dan rawatan selepas morfin 
secara kronik dengan mitraginin dalam pengeluaran adenosina monofosfat siklik 
(cAMP) ransangan oleh forskolin dan ekspresi reseptor mu-opioid (MOR) semasa 
pembezaan sel-sel manusia neuroblastoma SK-N-SH, mekanisme yang terlibat dalam 
perubahan tersebut, dan kesan pembezaan morfin dan mitraginin. cAMP adalah 
molekul yang dikawal oleh G protein-coupled reseptor pengaktifan dan lain-lain 
proses selular. Pengukuran cAMP dalam sel digunakan secara meluas sebagai 
penunjuk fungsi reseptor dalam aplikasi penemuan ubat-ubatan. Manakala perubahan 
dalam bilangan ekspresi MOR sebagai tindak balas kepada rawatan opioid kronik 
telah lama menjadi spekulasi secara langsung menyumbang kepada penyahpekaan 
reseptor dan pembangunan toleransi opioid. 
xvii 
Kesitotoksikan mitraginin terhadap sel SK-N-SH telah ditentukan. Mitraginin 
memperlihatkan kesan kepada kebergantungan dos dalam 50% perencatan 
percambahan sel pada kepekatan 77.268 μM. Pembangunan rawatan morfin kronik 
telah dioptimumkan. Tahap cAMP dalam sel-sel telah meningkat dengan ketara 
selepas 24 jam pengeraman dengan morfin sulfat berbanding dengan kawalan (sel 
sahaja). Sementara itu ekspresi reseptor mu-opioid menunjukkan kesan penurunan 
berbanding dengan kawalan. Menariknya mitraginin juga mempunyai kesan yang 
sama tetapi tahap kesan peningkatan cAMP dan kesan penurunan ekpresi MOR 
adalah kurang berbanding morfin. Dalam kajian ini rawatan bersama selama 24 jam 
diantara morfin sulfat dengan mitraginin menunjukan berkurangan pengeluaran 
cAMP pada kepekatan mitraginin yang lebih rendah berbanding dengan rawatan 
dengan morfin sulfat sahaja. Begitu juga pra rawatan dengan morfin sulfat selama 6 
jam, kemudian disambung dengan rawatan mitraginin selama 6 jam. Sementara itu, 
pada kepekatan tinggi, mitraginin akan menghasilkan kesan toleransi dan 
kebergantungan dengan meningkatkan pengeluaran tahap cAMP pada rangsangan 
foskolin. Kajian dalam ekspresi MOR, rawatan bersama morfin sulfat dengan 
mitraginin telah pengurangkan kesan mengurangan ekspresi MOR. Kajian in vitro ini 
menunjukkan mitraginin mempunyai potensi untuk mengelakkan toleransi dan 
kebergantungan rawatan morfin kronik pada kepekatan yang lebih rendah. Walau 
bagaimanapun ia akan mengakibatkan toleransi dan pergantungan pada kepekatan 
tinggi. 
 xviii 
THE EFFECT OF MITRAGYNINE ON CYCLIC AMP FORMATION AND 
mRNA EXPRESSION OF MU-OPIOID RECEPTORS MEDIATED BY 
CHRONIC MORPHINE TREATMENT IN SK-N-SH NEUROBLASTOMA 
CELL 
ABSTRACT 
Mitragynine is an indole alkaloid compound of Mitragyna speciosa 
(M.speciosa) Korth. (Rubiaceae). In Thailand, this plant is known as “Kratom” and 
in Malaysia it is known as “Biak-biak” or “Ketum”.  M. speciosa was used as 
substitution therapy for chronic opioid treatment to manage the withdrawal 
symptoms in Malaysia and Thailand. To date over 40 compounds have been isolated 
from the leaves of this plant. Mitragynine  is  the  most  abundant  of  the  more  than  
25  alkaloids of  Kratom  (66%  of  the  crude  base) and  is  responsible  for the  
substance’s  opioid  effects.  
The bioactive compound mitragynine from M.speciosa was isolated using 
acid-base extraction followed by a column chromatography method. In this study, we 
had investigated the cellular mechanism of chronic morphine treatment after co- and 
pre-treatment with mitragynine in production of forskolin stimulation cyclic 
adenosine monophosphate (cAMP) and expression of mu-opioid receptor (MOR) 
during the differentiation of SK-N-SH human neuroblastoma cells, the possible 
mechanisms involved in those changes, and the differential effects of morphine and 
mitragynine. cAMP is a molecule that is  controlled by G protein-coupled receptor 
activation and other cellular processes. Measurement of cAMP levels in cell is 
widely used as an indicator of receptors function in drug discovery application. 
Meanwhile changes in expression of MOR number in response to chronic opioid 
 xix 
treatment have long been speculated to directly contribute to receptor desensitization 
and the development of opioid tolerance 
The cytotoxicity of mitragynine on SK-N-SH cell was aslo determined. 
Mitragynine appeared to be dose-dependent in 50% inhibition of cell proliferation at 
concentration of 77.268 µM. Development of chronic morphine treatment was 
optimized. The cAMP level in the cells was significantly increased after 24 hours 
incubation with morphine sulphate as compared to the control (cell only). Meanwhile 
expression of mu-opioid receptor showed down-regulation as compared to the 
control. Interestingly mitragynine also has a similar effect but the up-regulation of 
cAMP level and down-regulation expression of MOR were less than morphine. In 
this study co-treatment for 24 hours between morphine sulphate with mitragynine 
significantly reduced the production of cyclic AMP at lower concentration of 
mitragynine as compared to treatment with morphine sulphate alone. Similarly 
pretreatment with morphine sulphate for 6 hours was carried out following treatment 
with mitragynine for 6 hours. Meanwhile at higher concentration, mitraygnine 
developed the tolerance and dependence by increasing the cAMP level production in 
foskolin stimulation. In the expression of mu-opioid receptor study, co-treatment of 
morphine sulphate with mitragynine had significantly reduced the down-regulation 
of MOR expression as compared to morphine treatment only. The present study 
showed mitragynine have the potential to avoid tolerance and dependence of chronic 
morphine treatment at lower concentration. However it will develop the tolerance 
and dependence at higher concentrations. 
1 
CHAPTER 1 
INTRODUCTION    
 
1.1 Medicinal Plant 
Plants play an important role in our lives. Besides providing us with food and 
shelter, they are also sources of medicine. Herbs may be defined as any plant that can 
be put into culinary or medicinal use and include those we associate with orthodox 
drugs such as opium poppy, as well as everyday plants like garlic or sage (WHO 
2003). 
 
In a previous year, herbal medicines are a common drug to increase and 
improve the physical performance or to treat human diseases. Despite the move 
towards technological medicine and the use of sophisticated drugs, traditional plant-
based remedies still play an important role in the world’s medicine. 80% of the 
world’s population still uses plant-based remedies as their primary form of healthcare 
(WHO, 2003). The use of plant-based medicines is a popular healthcare approach in 
Asia, Europe, North America and also being an important form of treatment in many 
developing countries, where it is part of the diverse local medical system (Heinrich et 
al., 2004). Although there are more than 20,000 herbs being used tody, only few 
herbal medicines have been proven safe by WHO (Ernst, 2004). 
 
 At present, there is an abundance of medicinal plant in the world that has 
been discovered with the potential to treat various kinds of diseases. The use of 
medicinal plants from the previous year may provide an indication about diseases 
and treatment that may conflict with the beliefs of people in the healthcare system 
(Morgan and Watkins, 1988). Therefore all medicinal plants may have a 
2 
recognizable therapeutic effect and also may have a toxic side effect that need to be 
studied (Keen et al., 1994).  
 
1.2 Safety concerns on the use of pharmaceutical from plant 
Popular belief has regarded that all medications come from natural resources 
are safe. Paracelsus, toxicology expert has made a statement concerning safety and 
his most popular quote is ‘all substances are poisons; there is none that is not a 
poison; the right dose differentiates a poison and a remedy’ (Timbrell, 2002). This 
statement is applies to all product including herbs. Houghton in an editorial note 
stressed the point that even in ‘problem plant’ (which refers to plants affecting the 
central nervous system, e.g opium), the correct dose and usege provide useful 
pharmaceuticals (Carlini, 2003). Most of the time, people use herbal medicines as 
dietary supplements to improve their health but the usage without prescription and 
precaution action. Herbal medicine should in fact be used with caution and advice 
from an expert to prevent common herbal medicines used in irregular, a high doses 
and in combination with other medication that may pose toxic side effect.  
 
The toxic side effects can range from an allergic reaction to hepatic failure, 
cardiovascular problem, neurological and dermatological effect. Sometimes the herb 
itself is not toxic. Toxicity arise because of adulteration occurs during preparation or 
processing (e.g. heavy metals), toxic effects may be exhibited such as poisoning by 
the Chinese herbal medicine podophyllum (But et al., 1996). Malaysia is a country 
that has a lot herbal medicines and this herbal medicine or pharmaceuticals from 
plants are regulated under a government agency, National Pharmaceutical Control 
Bureau (NPCB) which is also a WHO collaborating Centre for Regulatory Control of 
Pharmaceuticals. 
3 
1.3 Effect of plant on central nervous system 
In the last decades, the plant has been used as a source of drugs for treating 
human diseases (Chin et al., 2006). Some of the well-known plants first reported to 
have such use include poppy capsule latex (Papaver somniferum), myrrh 
(Commiphora species) and licorice (Glycyrrhiza glabra). The chemical entities 
derived from opium plant, P. somniferum such as papaverine, noscapine (narcotine), 
codeine and morphine are still used clinically (Newman et al., 2000). P. somniferum 
is the species of plant from which opium and poppy seeds are derived and has 
narcotic properties which mainly affect the function at the central nervous system 
(CNS). Morphine (and its derivative heroin), thebaine, codeine, papaverine, and 
noscapine are compounds that derived from this plant. Morphine was  used  as  
potent  painkillers  for  severe  pain  and has  made  this  plant  a  preferred choice for 
clinically used drugs. Until now, very few alternative drugs are proven to be as good 
as morphine as a potent painkiller for chronic pain management.  
 
Cannabinoid, a psychoactive compound from the plant Cannabis sativa also 
has a good  analgesic  effect  (Watts, 2004)  and  the  potential  to  treat  other  
neurological illnesses  (Fernández-Ruiz et al., 2007);  however  its  narcotic  effects  
and undesirable side  effects  such  as  addiction  and  high  potential  for  toxicity  
are drawbacks of its use and thus made it illegal in most countries. The cannabis 
plant is widely abused as a recreational drug and is well known as marijuana, ganja 
and has many other street names (Watts, 2006). Other alternative drugs of the kappa-
opioid group such as nalbuphine, pentazocine and butharphanol were clinically 
available as morphine alternatives but the controversy around the actual analgesic 
effects of these drugs remain debated (ScienceDaily, 2000) 
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 Other specific plants which are frequently used by the public and have direct 
and indirect effects on the central nervous system include Ephedra or Ma huang 
(Ephedra  spp),  which is a good nasal decongestants due to vasodilation effects 
however can also stimulate CNS side effects from nervousness to imsomnia (Tyler, 
1999). Gingko (Gingko biloba L.) a breakthrough herb in the late 1990’s, was found 
to be effective in improving cognitive performance and social functioning of 
demented patients, with a lower incidence of side effects. St. John’s wort (Hypericum 
perforatum  L.), one of  the five most popular herbs in the U.S.A was found can 
treating mild to moderate depression states (Tyler, 1999). Kava (Piper methysticum 
G.  Forst) which has a narcotic-like effects such as sedation and is effective in 
treating conditions such as nervous anxiety, stress and restlessness, was reported to 
have no addictive properties (Tyler, 1999). Valerian (Valeriana officinalis L.) which 
has been in use for a long time, has a reputation as a sleep aid and a mild tranquiliser 
but has been shown to produce CNS depression (Tyler, 1999). All this plants were 
reported have an affect on the central nervous system in the human body. Some of 
these plants have potential as a medicinal plant to treat various human diseases, but 
most of their misuse to get satisfaction as addiction. 
 
1.4 Drug addiction and withdrawal 
Drug addiction affects global health of a large community around the world 
and Statistical World Drug Report 2012 showed, 5% of the world’s adult populations 
are estimated to use drugs illegally and about 200,000 people about died each years 
because of drug abuse (UNODC, World Drug Report 2012). Addiction is 
characterized as a person initiate to force drug intake and followed by repeating of 
drug intake. This will cause loss of control in drug abuse and development of 
withdrawal symptoms when drug intake is discontinued. (Koob and Le Moal, 2008). 
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Drug addiction is a human behavior that consists of two disorders; impulse 
control disorders and compulsive disorder. In the early stages of addiction, 
impulsivity is a process that contribute to addiction, meanwhile the combination of 
impulsivity and compulsivity are involved in later stage of addiction. The impulse 
control disorder (ICD) is mainly controlled by the positive reinforcement and was 
characterized by failure to resist a temptation, repetitive engagement followed by 
increasing tension or arousal in specific behavior and impulse that may harm oneself 
or others. This mechanism leads to uncontrolled behavior (Grant and Potenza, 2004). 
Drug abuse will develop compulsivity after series of behavior. On the other hand, 
negative reinforcement mechanisms and voluntary responses mainly contributed to 
the compulsive disorder. Compulsive disorder (OCD) is an anxiety disorder which is 
characterized by uncontrollable, fear, repetitive behaviors and a combination of 
obsessions and compulsions (Koob et al., 2004). 
 
Study of pharmacological and psychological of the drugs should be included 
in the treatment of addiction behavior. The pharmacological study includes 
detoxification and attenuation of the drug withdrawal syndrome by traditional 
replacement therapy (van Dorp et al., 2007). Meanwhile psychological treatments of 
addiction will help by giving an opportunity to talk to the expert specially trained 
health professional in order to understand the symptoms, dealing with stress, self-
medicate and decreasing withdrawal related distress in patients (Baker et al., 2004).  
 
Prolonged drug intake, either voluntarily or involuntarily will cause the body 
system rapidly metabolize and remove the drugs from the body. However, once the 
body start to adapt to the drug, it will reduce the metabolism of drug release and 
increase the homeostatic mechanism can cause a phenomenon known as drug 
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withdrawal (G.A Barr  et al., 2011). Drug withdrawal syndrome is the 
discontinuation or reduces the use of drug, type of drug and quantity of drug used. 
Drug withdrawal syndrome will develop several physiological disorders and mental 
behavioral disorder. This syndrome also can cause severe symptoms such as flu-like, 
and include gastrointestinal distress, anxiety, nausea, insomnia, muscle pain, fevers, 
sweating, impatience depression and anger which began 6 to 8 hours after the last 
dosage (Cooper and Haney, 2009; Hughes et al., 1994). 
 
Detoxification is used in the treatment of patients who experience withdrawal 
symptoms followed by prolonged drug abuse. Detoxification in the drug withdrawal 
syndrome is a form of pharmacotherapy process with medical care to minimize and 
help patients from the drug abuse. This treatment usually used the agonist medication 
with the control dose in order to reduce the withdrawal symptoms from psychoactive 
drugs dependence (Margolin et al., 1995). After detoxification treatment, the 
pharmacotherapy treatment will be used to treat the behavioral and treatment long-
term rehabilitation. The rehabilitation process is a process more specific to prevent 
from drug abuse and improve the health of the patients. (McPeake et al., 1991; 
Schuler, 1993). However the combined treatment on pharmacological and 
physiological does not produce adequate therapeutic efficacies on drug addicts. 
Therefore, research on natural product for the development of drug that reduce the 
addiction currently are more toward to the understanding of the cellular, molecular 
and genetic pathways (Koob and Volkow, 2010) 
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1.5 Opioid drugs 
An opioid is a psychoactive chemical that bind to the opioid receptors such as 
μ, δ and κ, which are mostly found in the gastrointestinal tract and the central and 
peripheral nervous system. The receptors in these organ systems mediate both the 
side effects of opioids which can be both an indication of opioid administration side 
effect (Pert and Snyder, 1973) and can develop with ongoing administration, leading 
to a withdrawal syndrome that can produce a feeling of euphoria, motivating some to 
to recreational use of opioids (Harrison et al., 1998). Opioid is a generic term applied 
to opiates that are limited to natural alkaloids found in the resin of opium poppy 
(Papaver somniferum) and synthetic compound which have morphine-like properties 
and work at the opioid receptor. (Trescot et al., 2008). Most commonly opioids 
structure is an alkaloid base. Morphine, codeine, thebaine, papaerine and noscapine 
are natural alkaloid from plant resources. Heroin, methadone, buprenorphine, 
propoxyphene, pentazocine and oxycodone are synthetic opioid. A statistical report 
from the United Nation Office on Drugs and Crime (UNODC) in the year 2011, 
estimated 15 to 25 million aged 12 or older are opiate users in the United States. 
Heroin is the major contributing drug to the opiate user with 75% of the total number 
(UNODC, World Drug Report 2011).  
 
A major goal in opioid treating addiction is to reduce the severity of opioid 
withdrawal symptoms. Methadone and buprenorphine are opioid agonists most 
commonly used in the pharmacotherapy treatment to alleviate symptoms (Kosten and 
O'Connor, 2003). Prolonged usage of these treatments may lead to development 
another phase of addiction and dependence of the drug treatment (Kreek et al., 
2002). Therefore traditional medicine from natural resources may be comparable to 
8 
the existing medicine in treating the opioid withdrawal discomfort and it is found to 
be safer and has a less adverse effect (Shi et al., 2006). 
 
1.6 Molecular mechanisms of opioid addiction and withdrawal 
Biological mechanisms of opioid addiction can be divided into mediating 
tolerance, dependence and addiction. Since the discovery of morphine, researcher 
have tried to develop opioids with a reduced propensity to cause these negative 
sequel of prolonged opioid use (Connor et al., 2004). Morphine is a modern pain 
management therapy and the satisfactory treatment of chronic pain. In many cases 
morphine was used as a drug to prevent frustation by tolerance, dependence and drug 
addiction (Berger and Whistler, 2010). 
 
An acute opioid effect will activate several potential mechanisms in the 
specific region of the brains. These mechanisms include the inhibition of calcium 
conductance, inhibition adenylyl cyclase that cause a reduction in cAMP level, 
activation of potassium conductance and acute inhibition of transmitters released by 
opioids (Williams et al., 2001). Meanwhile withdrawal from chronic treatment with 
morphine will superactivate adenylyl cyclase activity that increases the production of 
cAMP level, deactivate voltage-dependent potassium currents to inhibit potassium 
release and increases transmitter release through activation of PKA (Williams et al., 
2001). Another mechanism involved in chronic opioid action is opioid receptor 
internalization, recycling and downregulation (Koch and Hollt, 2008). 
 
Exposure of drug to the cells may cause persistent changes in the brain such 
as changes in the protein expression, protein-protein interactions and gene 
expression. Therefore it will affect the network behavior responses in the subjects. 
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The repeated exposure to a drug abuser could alter gene expression in the brain such 
as alteration of gene transcription, alteration of primary RNA transcripts into mature 
mRNAs, alteration translation of these mRNAs into proteins and processing of 
protein and alteration of traﬃcking mature proteins to their intracellular sites of 
action. (Nestler, 2004).  
 
The most commonly reported actions on drug addiction on a cellular level 
include regulation of adenylyl cyclase activity, inhibition of transmitter release, 
activity of calcium conductance, potassium conductance and activation of any of the 
three opioid receptor subtypes. More recent observations have extended the actions 
of opioids to include the activation of protein kinase C (PKC), the release of calcium 
from extracellular stores, the  activation  of  the  mitogen-activated  protein kinase 
(MAPK) cascade, and the realization that receptor trafﬁcking plays an important role 
in receptor’s function (Figure 1.1) (Williams et al., 2001). Therefore the current 
trend in the neuroscience research focuses on the basic cellular and molecular 
pathways in the development of addiction and complex behaviour over drug seeking. 
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1.7 Cyclic adenosine monophosphate (cAMP) as potential drug targets 
Adenylate cyclase is a two-component enzyme system. It ultimately catalyses 
the cyclase reaction, but only when it is associated with the hormone-bound receptor 
and a regulatory protein called stimulatory G-protein (guanylate nucleotide binding 
protein), which activates adenylate cyclase. The G-protein is the intermediate 
between the receptor and the synthesis of cyclic AMP (CliffsNotes.com.). cAMP was 
discovered in the 1960s and the cloning of the first adenylyl cyclase (AC) began in 
the 1990s. cAMP and its generating enzymes have been shown to play crucial roles 
in both physiological and pathophysiological settings and have evolved as targets for 
drug development for numerous diseases (Williams, 2004). The formation of cyclic 
AMP can be activated by a very large number of cell stimuli, mainly 
neurotransmitters and hormones.  All these stimuli are detected by G-protein-coupled 
receptors (GPCRs) that use heterotrimeric G proteins, which are the transducers that 
are responsible for either activating or inhibiting the enzyme AC (Pierre et al., 2009). 
 
The best studied to determine to tolerance and withdrawal effect is inhibition 
of adenylyl cyclase as an assay (Christie, 2008). Opiates inhibit the functional 
activity of the cAMP pathway by inhibiting adenylyl cyclase, the enzyme that 
catalyzes the synthesis of cAMP. The inhibition of the cAMP pathway will recoverto 
normal with continued exposure of an opioid drug, which can be viewed as a sign of 
tolerance. This recovery can also be viewed as a sign of dependence. After removal 
of the opioid drug (e.g., by administration of an opioid receptor antagonist, such as 
naloxone), the activity of the cAMP level increases above control levels, which can 
be viewed as a sign of withdrawal. (Figure 1.2) (Nestler, 2004). 
 
12 
 A chronic opioid treatment that induced adaptive sensitization or an 
overshoot adenylate cyclase activity and increased cAMP level has been observed in 
NG108-15 cells (Musacchio and Greenspan, 1986), SK-N-SH cells  (Wang et al., 
1994), SHSY-5Y cells (Yu et al., 2003) and mu-opioid receptor-transfected CHO 
(Avidor-Reiss et al., 1995), and HEK293  cells (Blake et al., 1997).  
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Figure 1.2: Model of cAMP responsiveness in cells treated chronically with        
morphine. Gray bar represents an idealized situation, in which cells 
respond robustly to morphine (A) and retain equivalent responsiveness 
as long as the drug is present (B, gray bar). When the drug is 
withdrawn, cAMP returns to the same baseline as in naive cells (C, gray 
bar). In the idealized situation, reapplication of drug (2) leads to 
equivalent inhibition as naive cells (D, gray bar) (Finn and Whistler, 
2001) 
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1.8 Opioid receptor downregulation 
1.8.1 Opioid receptors  
Opioid drug produces a mechanism effect on neurons by acting on receptors 
located on the cell membranes. Opioid receptors are receptors belonging to the seven 
transmembrane spanning (7TM) G protein-coupled receptors (GPCRs). 
Physiological importance of these receptors include mediating the actions of the 
majority of known neurotransmitters and hormones (Waldhoer et al., 2004). Three 
major types of opioid receptor’s μ, δ and κ, had been defined pharmacologically 
several years ago. Activation of opioid receptors is from opioid peptides that were 
produced endogenous by when the opioid drug was administered. Morphine is an 
agonist compound that has a higher affinity for mu receptor than other opioid 
receptor and exhibited the most effective analgesic activities. (Hughes and Kosterlitz, 
1983). μ, δ and κ-receptors have analgesia effect when an opioid bind to them. 
However, activation of κ-receptors do not produce as much physical dependence as 
activation of μ-receptors (Waldhoer et al., 2004). 
 
1.8.2 μ-opioid receptor (MOR) internalization, recycling and down-regulation 
 At the cellular level, loss of responsiveness to an agonist is also a recurrent 
theme in the field of G-protein coupled receptors (GPCR), including the μ-opioid 
receptor (MOR). Three major processes of loss of responsiveness to be involved 
have been characterized. These ligand-induced processes include loss of G-protein 
coupling to the receptor, receptor internalization, where the receptor is sequestered 
from the cell surface, and receptor down-regulation, which is defined as the 
reduction in the total number of receptors (Horner and Zadina, 2004). Desensitization 
was defined as the loss of responsiveness of receptor’s function under continuing or 
increasing exposure to an agonist. The key to the initial event for acute receptor 
15 
desensitization is receptor’s phosphorylation in the cells. This suggestion has been 
supported and demonstrated in an increased MOR phosphorylation as proven in 
transfected Chinese hamster ovary (CHO) cells (Zhang et al., 1996) and HEK293 
cells (Schulz et al., 2004) as well as in MOR expressing neuronal cells in prolonged 
opioid exposure (Deng et al., 2001).  
 
Mechanisms for the desensitization of opioid receptor not only comprised of 
phosphorylation and uncoupling of the receptor from G proteins, but they are 
followed by receptor internalization and downregulation of receptors. Receptor 
internalization is a first process in downregulation of a receptor after chronic 
exposure to an agonist. In this process, receptors were internalized into endosomes 
and moved to the lysosomes for a degradation process. (Ferguson et al., 1996). The 
process of internalization of GPCR by an agonist occurs before the downregulation 
process of a receptor. After internalization, opioid receptors are either recycled from 
endosomes to the plasma membrane or trafficked to lysosomes/proteasomes for 
degradation process. Downregulation of opioid receptors after chronic opioid 
treatment is a long-term-adaptive process that may result from degradation of 
internalized receptors and/or from a decrease of receptor synthesis (Koch and Hollt, 
2008). A previous report showed more than 80% of internalized receptors were 
recycled after 30 min of DAMGO treatment, but receptors could be substantially 
down-regulated (i.e. >60%) after only 2 h of DAMGO treatments (Polakiewicz et al., 
1998).  
 
Receptor desensitization and changes in the MOR number after chronic 
opioid treatment have long been speculated to directly contribute to the development 
of opioid tolerance. First of all, receptor down regulation after chronic opioid 
16 
exposure has been clearly demonstrated only in vitro (Yabaluri and Medzihradsky, 
1997), whereas in vivo results are highly variable (Zadina et al., 1995). Following 
chronic treatment with various agonists, opioid receptors in the brain have been 
reported to decrease (Tao et al., 1987; Zadina et al., 1995) or to remain unchanged 
(Hollt et al., 1975) indicating that down regulation of opioid receptors depends on 
opioid species, and brain regions tested. Moreover, there are ligand-specific 
differences in the ability of μ-opioids to cause receptor down regulation that do not 
correlate with differences in tolerance (Patel et al., 2002). 
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1.9 Historical overview of Mitragyna speciosa 
1.9.1 Mitragyna Speciosa 
Mitragyna speciosa (M. speciosa) Korth belongs to the family Rubiaceae and 
genus mitragyna and can usually be found in tropical and subtropical Asia such as 
Malaysia, Thailand, Laos and Cambodia (Houghton and Said, 1986). In Malaysia, 
this plant is locally known as ‘ketum’ or ‘biak-biak’ and is indigenous in  the  
swampy  area  especially  in  the  northern  and  west  coast  part  of  Peninsular 
Malaysia, in the states of Perlis, Kedah, Kelantan and Terengganu and also in the 
west coast states like Selangor and Perak. In Thailand, this plant is well known as 
‘ithang’, ‘thom’, ’kakuam’ or ‘kratom’. However, people globally recognise this 
plant as ‘Kratom’. The genus was given its name by Pieter Willem Korthals, official 
botanist with the Dutch East India Service from 1831 to 1836, because the flower 
stigmas in the first species he examined resembled the shape of a bishop's miter.  
 
M. Speciosa (Figure 1.4) reaches heights of 30-60 feet with a branch spread 
of over 10-20 feet. Flowers are yellow and grow in ball-shaped clusters and the stem 
is erect and branching. Leaves are dark glossy green in colour, smooth, ovate-
acuminate in shape, and opposite in growth pattern. Leaves can grow over 7 inches 
long and 4 inches wide. M .speciosa is evergreen rather than deciduous, and leaves 
are constantly being shed and being replaced, but there is some quasi-seasonal leaf 
shedding due to environmental conditions. During the dry season of the year, leaf fall 
is more abundant, and new growth is more plentiful during the rainy season. When 
grown outside their natural tropical habitat, leaf fall occurs with colder temperatures, 
around 4° Celsius. There are two main varieties of this  plant  which  can  be  
differentiated  by  its  leaves.   
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The scientific classification of M. Speciosa (Korthals, 1839) is shown as follows: 
 
Kingdom:  Plantae 
Division:  Magnoliophyta 
Order:   Gentianales 
Family:  Rubiaceae 
Genus:  Mitragyna 
Species:  M. speciosa 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Classification of M. speciosa leaves and morphology of plant. 
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The  leaves  have  special characteristics which are easily distinguishable in which 
the petiole (vein) could either  be  red  or  white-greenish  and  it  was  believed  that  
they  produced  different strength  of  effects  (Murple, 2006).  The  leaves  with  red-
greenish  type  of  vein were suggested to have stronger effects (Suwanlert, 1975). 
 
1.9.2 Chemical constituents of the M. speciosa 
More than 45 compounds have been isolated (Adkins et al., 2011) and over 
25 alkaloids have been isolated from M. speciosa, most of which are yohimbe-type 
indoles and oxindoles (Figure 1.5) (Houghton and Said, 1986). Alkaloids are a group 
of compouds containing the basic nitrogen atom in the naturally chemical compound. 
This group also includes some related compounds with neutral and even weak acidic 
properties. A rough estimate is that more than one-quarter of all known alkaloids are 
indoles. All approaches in clarifying pathways of alkaloid metabolism have been 
applied to the indole alkaloids and perhaps because of their rich complexity, these 
compounds seem to have been endowed with a greater variety of hypothetical 
metabolic pathways than any other groups (Hilaire, 1981). 
 
There are six indoles alkaloids found in M. speciosa; mitragynine, 7-
hydroxymitragynine, paynanthine, speciogynine, speciociliatine and corynantheidine 
(Figure 1.6). Mitragynine and 7-hydroxymitragynine are unique to this species and 
most studied. The two oxindoles are mitraphylline and speciofoline. Other alkaloids 
present include other indoles and oxindoles such as ajmalicine, akuammigine, 
corynanthedine, mitraversine, rhynchophylline, speciociliatine (also unique to M. 
speciosa) and stipulatine (Hassan et al., 2013). 
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Table 1.1: Alkaloid proﬁle of Mitragyna speciosa Korth. The percentage is the 
estimated content in the alkaloid extracts (Hassan et al., 2013) 
Alkaloid Percentage Effect 
Mitragynine 66% Analgesic, antitussive, antidiarrheal, 
adrenergic, antimalarial 
Paynantheine 9% Smooth muscle relaxer 
Speciogynine 7% Smooth muscle relaxer 
7-Hydroxymitragynine 2% Analgesic, antitussive, antidiarrheal 
Speciociliatine 1% Weak opiod agonist 
Mitraphylline <1% Vasodilator, antihypertensive, muscle 
relaxer,diuretic, antiamnesic 
Isomitraphyline <1% Immunostimulant, anti-leukemic 
Speciophylline <1% Anti-leukemic 
Rhynchophylline <1% Vasodilator, antihypertensive, calcium 
channel blocker, antiaggregant, anti-
inflammatory, antipyretic, anti-arrhythmic, 
antithelmintic 
Isorhynchophylline <1% Immunostimulant 
Ajmalicine <1% Cerebrocirculant, antiaggregant, anti-
adrenergic, sedative, anticonvulsant, smooth 
muscle relaxer 
Corynantheidine <1% Opioid agonist 
Corynoxine A <1% Calcium channel blocker, anti-locomotive 
Corynoxine B <1% Anti-locomotive 
Mitrafoline <1%  
Isomitrafoline <1%  
Oxindale A <1%  
Oxindole B <1%  
Speciofoline <1% Analgesic, antitussive 
Isospeciofoline <1%  
Ciliaphylline <1% Analgesic, antitussive 
Mitraciliatine <1%  
Mitragynaline <1%  
Mitragynalinic acid <1%  
Corynantheidalinic acid <1%  
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Figure 1.5:  Chemical structure of mitragynine and its major analogues  
                   (Hassan et al., 2013) 
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Mitragynine is the major compound with 66% of the total alkaloid mixture 
derived from these leaves. Most studies suggest mitragynine as the main chemical 
responsible for the effects of the activity of this herb. Mitragynine was isolated in 
1907 by Hooper followed by Field (1921) and the structure of mitragynine was 
determined by Zacharias (1964). In the 1960s, the Chelsea group in the U.K. reported 
the isolation of several indole alkaloids from the leaves of M. speciosa from 
Thailand. Mitragynine compound was synthesized by Takayama et al., 1995 and 
alternative synthesis was reported later by Ma et al. (2009). A computational study 
recently identified the lowest energy conformation of mitragynine which was in 
excellent agreement with X-ray crystal structure geometry (Hassan et al., 2013). 
Mitragynine is a white amorphous powder, it is soluble in alcohol, chloroform and 
acetic acid. The chemical structure of mitragynine is related to both yohimbine and 
voacangine. Chemically, mitragynine is 9-methoxy-corynantheidine. 
 
1.9.3 Pharmacology of M. speciosa and mitragynine 
M. speciosa  Korth  plant,  especially  its  leaves has been consumed  since  
time  immemorial,  where  village  people  such  as  farmers  and  labourers  chew  
the fresh leaves, smoke the dry leaves or drink as a tea suspension or  even  eat  it  in  
the  form  of  resin,  for  the stimulant effects  to  overcome  the  burden  of  hard  
work  under  the scorching sun.    It  was  way  back  in  1897 when  the  leaves and 
the bark of this plant were reported by Ridley as a cure for opium habit and was  
further  quoted  by  Hooper  in  1907.  In the same year, Holmes also referred to its 
leaves as an opium substitute (Shellard, 1974). This plant has unique dual opioid 
properties which exert a stimulant effect  at  low  doses  and  sedative  and  analgesic  
effects  at  higher  doses  in humans (Suwanlert, 1975). These effects have also been 
observed in animal models as reported by Macko et al (1972). 
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It was also reported that M. speciosa has effect of depression such as 
cannabis and opium and psychostimulant effects such as coca. (Jansen and Prast, 
1988). Mitragynine has weaker effects than morphine, less harmful than cocaine and 
has a milder withdrawal syndrome compared to opioids. In Malaysia and Thailand, 
local people used M.speciosa leaveas as a substitution therapy for chronic opioid 
treatment to manage withdrawal symptoms especially on treatment substitution of 
morphine and heroin (Matsumoto et al., 2004b; Vicknasingam et al., 2010). Besides 
that, it has been used as a traditional medicine for the treatment of common illnesses 
such as hypertension, coughing, muscle pain, diarrhoea and also used as a tonic to 
regain the energy (Jansen and Prast, 1988). 
 
Mitragynine showed unique effects on the phytochemical and 
pharmacological study (Chee et al., 2008).  In vivo  and in vitro pharmacological  
investigations revealed that M. speciosa has antinociceptive, antidepressant, 
antioxidant, antibacterial and antitussive activities (Chittrakarn et al., 2008; Idayu et 
al., 2011; Matsumoto et al., 2005; Parthasarathy et al., 2009; Sabetghadam et al., 
2010). Crude extract of M. speciosa and mitragynine were also reported to have 
analgesic properties both in-vivo and in-vitro (Matsumoto et al., 2004a; 
Reanmongkol, 2007). The crude methanol (MeOH) extract was used in an in-vitro 
assay on electric stimulation of guinea-pig ileum in which the opioid antagonist, 
naloxone, successfully inhibited the contraction. This implies that the crude extract is 
an opioid agonist (Takayama, 2004).  
 
Crude extract of M.speciosa and mitragynine were also reported to 
successfully act via supraspinal µ, δ and κ opioid receptors (Thongpradichote et al., 
